Tarantino, Paolo

Optimizing the safety of antibody–drug conjugates for patients with solid tumours

Tarantino, P., Ricciuti, B., Pradhan, S. M., & Tolaney, S. M. (2023) · Nature Reviews Clinical Oncology

Monoclonal and Polyclonal Antibodies ResearchCancer Immunotherapy and Biomarkers

Cited by 269

The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development

Colombo, R., Tarantino, P., Rich, J. R., LoRusso, P. M., & de Vries, E. G. E. (2024) · Cancer Discovery

Monoclonal and Polyclonal Antibodies ResearchToxin Mechanisms and Immunotoxins

Cited by 254

Next Generation Sequencing (NGS): A Revolutionary Technology in Pharmacogenomics and Personalized Medicine in Cancer

Morganti, S., Tarantino, P., Ferraro, E., D’Amico, P., Duso, B. A., & Curigliano, G. (2019) · Advances in Experimental Medicine and Biology

Cancer Genomics and DiagnosticsGenomics and Rare Diseases

Cited by 246

Unleashing the power of anti-HER2 therapies in metastatic colorectal cancer: paving the way for a brighter future

Babkoff, A., Zick, A., Hubert, A., Tarantino, P., & Grinshpun, A. (2024) · ESMO Gastrointestinal Oncology

Colorectal Cancer Treatments and StudiesHER2/EGFR in Cancer Research

Cited by 14

Development and validation of a human-supervised AI-augmented living oncology evidence platform: a breast cancer pilot study

Rugo, H., Forsythe, A., Flora, D., Glück, S., Grieve, S., Campden, R., Liu, R. J., Musat, M., Rege, J. M., Kaufman, P. A., et al. (2026) · ESMO Real World Data and Digital Oncology

Artificial Intelligence in Healthcare and EducationMeta-analysis and systematic reviews

Cited by 0